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Introduction
Two cases of successful cadaveric renal transplantation
in patients with the Wiskott-Aldrich syndrome have
previously been reported in the literature [1,2]. The
first patient [1] had an almost uneventful outcome,
while the second one [2] had to be treated with high-
dose methylprednisolone for biopsy-proven cellular
rejection. The optimal immunosuppressive regimen in
patients with Wiskott-Aldrich syndrome remains
unknown. We report here the case of a
Wiskott-Aldrich patient who underwent living-related
renal transplantation. This patient however developed
a number of infectious and non-infectious complica-
tions which led to his death 3 months after
transplantation.
Case report
The patient, a 41-year-old man with a strong family
history of an X-linked transmitted syndrome (17 affec-
ted men and 10 female carriers in the last three
generations), presented in early childhood with severe
thrombocytopenia, allergic eczema, and recurrent
infections (bronchitis, herpetic keratitis). Since 1982
he had developed progressive renal insufficiency with
microhaematuria and proteinuria, which was presumed
to be due to I gA nephropathy (no biopsy was
obtained, but a brother of the patient who died at the
age of 32 suffered from the Wiskott-Aldrich syndrome
and developed end-stage renal failure due to biopsy-
proven I gA nephropathy). Haemodialysis treatment
was started in April 1991. In preparation for renal
transplantation the patient underwent splenectomy in
Correspondence and offprint requests to: Prof. Gilbert Thiel, Division
of Nephrology, Department of Internal Medicine, Kantonsspital,
Petersgraben 4, CH^031 Basel, Switzerland.
January 1994, which resulted in normalization of the
platelet count.
In August 1994 he received a one-haplotype-matched
living-related kidney graft (the donor was his father
born in 1925). CMV constellation was donor positive/
recipient positive. Epstein-Barr virus serology was
I gG positive and I gM negative for both recipient and
donor. Because of the underlying immunosuppression,
our usual induction protocol (quadruple therapy
including antithymocyte globulin (ATG), azathioprine
(Aza), prednisone (Pred), and CsA was modified by
omitting ATG. CsA (dose adjusted to maintain a
trough whole-blood level of 200-250 ng/ml), Aza
(2 mg/kg), and methylprednisolone (1 g, 0.5 g, 0.25 g
intravenously respectively on day 0, 1, 2) tapered to
0.5 mg/kg Pred by day 3 were administered as usual.
The onset of renal function was prompt. On day 5
creatinine increased and three methylprednisolone
pulses were administered. Transplant biopsy failed to
confirm rejection and functional CsA toxicity was
suspected. Creatinine decreased (151 umol/1 on
day 14). On day 22 creatinine increased to 229 umol/1
and a second renal biopsy showed a moderate infiltr-
ative and proliferative transplant vasculopathy with
areas of arteriolar necrosis. ATG (0.2 ml/kg per day)
was administered for 7 days with a good effect on
renal function.
On day 30 the patient developed CMV disease and
was treated with ganciclovir. Because of severe leukop-
enia filgrastim was administered over 5 days. On day 39
a catheter sepsis with coagulase-negative staphylococci
was diagnosed and treated with vancomycin. On
day 46, several herpes zoster vesicles appeared on the
plantar edge of the left foot. On day 52 the patient
developed fever and paroxysmal excruciating pain radi-
ating to the left lower limb with a SI dermatome
topography. Acyclovir was administered and clona-
zepam was necessary to control pain, which was inter-
preted as zoster neuralgia. From days 76 to 78 the
patient was given three methylprednisolone pulses for
biopsy-proven interstitial rejection (creatinine
237 umol/1.).
High fever appeared associated with rising liver
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enzymes (ASAT up to 858 U/l, ALAT up to 369 U/l).
Ganciclovir and imipenem were given but without
improvement of the patient's condition. A liver biopsy
on day 88 revealed a malignant high-grade B-cell non-
Hodgkin lymphoma (large-cell immunoblastic accord-
ing to International Working Formulation) with mas-
sive periportal infiltration. A thoracoabdominal CT
scan and bone marrow aspiration failed to demonstrate
any other foci of the lymphoma. CsA was stopped on
day 88 and a first cycle of chemotherapy consisting of
adriamycin and cyclophosphamide was administered.
On the same day, Pneumocystis carinii pneumonia was
diagnosed and treatment with co-trimoxazole was insti-
tuted. Haemodialysis was then started because of pro-
gressive oliguria. On day 91 the patient developed
massive epistaxis and melena requiring transfusional
support; platelets had decreased to 38000/mm3. Two
days later a subdural haematoma was diagnosed by
CT scan.
Over the following days the patient's condition
rapidly deteriorated. He became unresponsive,
developed severe hypotension, and died on day 98.
Autopsy was not performed because of family refusal.
Post-mortem liver biopsy showed persistent lymphoma.
Post-mortem transplant biopsy showed mild sclerotic
transplant vasculopathy.
Discussion
The Wiskott-Aldrich syndrome is a rare X-linked
syndrome associating B- and T-cell immunodeficiency,
thrombocytopenia, and eczema. As recently described
[3,4] there is a defective expression of the CD43
molecule on T cells, which may compromise the antigen
specific activation of T cells by impairing interaction
with ICAM-1. This same mechanism may underlie the
propensity for infections and the increased incidence
of B-cell lymphoma for which this syndrome is known
[5]. The ideal treatment for patients with the
Wiskott-Aldrich syndrome is HLA-identical bone-
marrow transplantation from a sibling donor, which
cures the underlying immunodeficiency, although such
donors are available for only a few Wiskott-Aldrich
patients [6,7]. An alternative therapeutic approach is
splenectomy, which has been shown to improve both
survival and quality of life [7].
One variant of the syndrome is associated with I gA
nephropathy, potentially leading to end-stage renal
failure [8-10]. Renal transplantation is not usually
recommended in this condition because of the under-
lying immunodeficiency and the increased risk of
lymphoma. The patient reported by Webb et al. [1]
was given a reduced immunosuppressive regimen
(triple therapy with Aza in a reduced dose, CsA, and
Pred). There was no rejection episode and a primary
CMV seroconversion illness resolved rapidly after
treatment with anti-CMV hyperimmune globulins. A
very similar immunosuppressive regimen was initially
used by Meisels et al. [2]; Aza had to be discontinued
on day 12 because of thrombocytopenia. Their patient,
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however, had to be treated twice with high-dose
methylprednisolone, the first time for clinically sus-
pected rejection, the second time for biopsy-proven
cellular rejection. This shows that despite the under-
lying defect in cellular immunity their patient was able
to develop an immune response to allograft antigens.
Our patient underwent a one-haplotype-matched
living-related renal transplantation. He received two
courses of high dose methylprednisolone, and was
additionally treated with ATG because of vascular
rejection. The following course proceeded to the
dreaded 'worst-case scenario': several infectious com-
plications followed each other in rapid succession and
a fatal high grade B-cell lymphoma of the liver
developed.
Such a dramatic outcome raises ethical as well as
medical considerations. Our observation suggests that
renal transplantation remains a high-risk procedure in
patients with the Wiskott-Aldrich syndrome. These
patients are able to mount a severe rejection reaction
against the transplanted kidney and their increased
propensity to develop lymphoma limits drastically the
therapeutic possibilities if such a rejection occurs.
Retrospectively it is evident that we superseded this
limitation. We probably should have reduced the
amount of Aza in our induction protocol, and certainly
should not have used ATG at all. The patient was a
perfectly well-informed man working in a leading
paramedical position. Every step in his treatment was
thoroughly discussed and our error was to accept his
willingness to undergo a risky treatment. Is it at all
ethical to transplant a patient with the Wiskott-Aldrich
syndrome? The answer to this question depends prob-
ably most on the subjective quality of life during
chronic dialysis treatment. If renal transplantation is
attempted, Aza dose is to be reduced and antilympho-
cyte globulins are to be strictly avoided, even if this
means rapidly losing the graft.
References
1. Webb MC, Andrews PA, Koffman CG, Cameron JS. Renal
transplantation in Wiskott-Aldrich syndrome. Transplantation
1993; 56: 747-748
2. Meisels IS, Strom TB, Roy-Chaudhury P et al. Renal allograft
rejection in a patient with the Wiskott-Aldrich syndrome.
Transplantation 1995; 59: 1214-1215
3. Park JK, Rosenstein YJ, Remold-O'Donnel E, Bierer BE, Rosen
FS, Burakoff SJ. Enhancement of T-cell activation by the CD
43 molecule whose expression is defective in Wiskott-Aldrich
syndrome. Nature 1991; 350: 706-709
4. Rosenstein YJ, Park JK, Hahn WC, Rosen FS, Bierer BE,
Burakoff SJ. CD 43, a molecule defective in Wiskott-Aldrich
syndrome binds ICAM-1. Nature 1991; 354: 233-235
5. Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES.
Malignant lymphoma in patients with the Wiskott-Aldrich
syndrome. Cancer Invest 1985; 3: 515-522
6. Rimm IJ, Rappeport JM. Bone marrow transplantation for the
Wiskott-Aldrich syndrome. Long-term follow-up.
Transplantation 1990; 50: 617-620
7. Mullen CA, Anderson KD, Blaese M. Splenectomy and/or bone
marrow transplantation in the management of the
Wiskott-Aldrich syndrome: long-term follow-up of 62 cases.
Blood 1993; 82: 2961-2966
Fatal outcome of renal transplantation in Wiskott-Aldrich syndrome
8. Guttenberger J, Trygstad CW, Stiehm ER el at. Familial throm-
bocytopenia, elevated serum I gA levels and renal disease. A
report of kindred. Am J Med 1970; 49: 729-741
9. Standen GR, Lillicrap DP, Mathews N, Bloom AL. Inherited
thrombocytopenia, elevated serum I gA and renal disease.
Identification of a variant of the Wiskott-Aldrich syndrome. Q
J Med 1986; 59: 401^08
10. Spittler LE, Wray BB, Morgenmanns S, Miller JJ, O'Reilly RJ,
Lagios M. Nephropathy in the Wiskott-Aldnch syndrome.
Pediatrics 1980; 66: 391-398
2079
Received for publication' 1.12.95
Accepted in revised form. 8.12 95
Editor's note
Please see also The Interesting
(pp. 2093-2095 in this issue).
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